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Smooth muscle myosin light chain (LC) can be phosphorylated by myosin light chain kihase (MLCK) at Ser” and Thr’” and by protein kinase 
C (PKC) at Thr9 and Ser’ or Se? under the in vitro assay conditions. Conversion of PKC to the spontaneously active protein kinase M (PKM) 
by proteolysis resulted in a change in the substrate specificity of the kinase. PKM phosphorylated both sets of sites in LC recognized by MLCK 
and PKC as analyzed by peptide mapping analysis. The PKM-catalyzed phosphorylation of these sites was not greatly affected by a MLCK 
inhibitor, ML-9, nor by the activators of MLCK, Ca*’ and calmodulin. 
Protein kinase C; Myosin light chain; Phosphorylation 
1, INTRODUCTION 
Phosphorylation of the 20 kDa smooth muscle myo- 
sin light chains (LC) is recognized as a key process in 
the regulation of smooth muscle concentration [1,2]. 
Both myosin light chain kinase (MLCK), a Ca*‘/calmo- 
dulin-activated protein kinase, and protein kinase C 
(PKC), a Ca*‘/phospholipid-activated protein kinase, 
have been shown to phosphorylate LC and have been 
implicated in the regulation of the actin-activated Mg2+- 
ATPase activity [2]. MLCK phosphorylates smooth 
muscle LC at Ser” and Thr’* in sequence resulting in an 
increase in the actin-activated Mg*‘-ATPase activity [3- 
5]. In contrast, PKC phosphorylates Thr’ and Ser’ or 
Ser* with a resulting decrease in the Mg*‘-ATPase activ- 
ity of myosin that has already been activated by MLCK 
[5-71. Phosphorylation of the LC by PKC also decreases 
the rate of subsequent phosphorylation of the LC by 
MLCK [6]. PKC-catalyzed phosphorylation of myosin 
LC has been suggested to inhibit the contractile re- 
sponse of smooth muscle in vivo by counteracting the 
activation by MLCK [5,6]. 
It has been reported that incubation of human plate- 
lets with thrombin or phorbol 12-myristate, 13-acetate 
(PMA), an activator of PKC, caused the phosphoryla- 
tion of myosin LC at 2 sets of sites recognized separately 
by PKC and MLCK under the in vitro assay conditions 
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[8]. It was suggested that treatment of the platelets with 
PMA also resulted in an increase in [Ca”], and thereby 
caused an activation of MLCK. Because treatment of 
human platelets with phorbol esters also enhances the 
generation of PKM [9], we tested the possibility of 
whether PKM alone could phosphorylate the LC at 
both sets of sites recognized by PKC and MLCK. In 
this report we compare the phosphorylation of smooth 
muscle LC by MLCK, PKC and PKM. Our results 
show that PKM catalyzes the phosphorylation of the 
LC to a higher stoichiometry than that by PKC or 
MLCK. Peptide mapping analysis revealed that PKM 
phosphoryiated both sets of sites recognized by PKC 
and MLCK. The PKM-catalyzed phosphorylation of 
these sites was not greatly inhibited by a MLCK inhib- 
itor, ML-9, nor activated by the activators of MLCK, 
Ca2* and calmodulin. These results indicate that the 
substrate specificity of PKC can be altered following its 
conversion to PKM. 
2. MATERIALS AND METHODS 
The following materials were obtained from the indicated sources: 
Histone IIIS, EGTA and soybean trypsin inhibitor from Sigma; [y- 
‘*P]ATP, and [‘*‘I]protein A from DuPont-New England Nuclear; 
phosphatidylserine (PS) and dioleoylglycerol from Avanti Polar Li- 
pids; peptide KISSNH, corresponding to the amino acid sequence of 
turkey gizzard myosin light chain II-22 (KKRPQRATSNVF) [IO] 
from Peninsula Laboratories; calmodulin from Calbiochem; Ampho- 
line solutions from Pharmacia LKB Biotechnology; TPKC-trypsin 
from Worthington; phosphocellulose P-81 paper from Whatman; Si- 
lica Gel 60 thin-layer plate from EM Science; ML-9 (I -(5-chloronaph- 
thalene-1-sulfonyl)-IH-hexahydro-l,4-diazepine) from Seikagaku 
America Inc.; and rabbit anti-turkey gizzard MLCK antiserum was 
kindly provided by Dr. Mary D. Pato. Rat brain PKC [I I] and the 
catalytic fragment of PKC, PKM 1121, were purified to near homoge- 
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neity as described previously. MLCK [ 131 and myosin LC, a mixture 
of the 20 and 17 kDa LCs [14], were purified from turkey gizzard. 
Phosphorylation of the LC was carried out at 30°C in a basic 
reaction mixture containing 30 mM Tris-[ICI buffer, pH 7.5, 6 mM 
M&I,, 0.2 mM (y-“P]ATP, 0.4 mg/ml LC. Additional ingredients 
were added to the basic reaction mixture for the assay of the various 
protein kinases: 50 pg/ml L’S, 10 pg/ml DAG and 0.4 mM CaCI, for 
PKC; 0.4 mM EGTA for PKM; and 0.1 PM calmodulin and 0.16 mM 
CaCI, for MLCK. Reactions were initiated by the addition of the 
kinases. Measurement of “P-incorporation into the protein substrate 
and the peptide K13SNHz was as previously described [15]. 
Digestion of “P-labeled LC by trypsin was carried out in 50 mM 
NH,HCO,. pH 8.5, for 16 h at 30°C. Isoelectric focusing of the 
‘ZP-labeled tryptic peptides on polyacrylamide gel (1 mm thickness) 
was carried out at 4°C for 60 min with a power setting of 30 W and 
maximal voltage setting of 1500 V using 1 M H,PO,, as the anode 
solution and 1 M NaOH as the cathode solution. A plate of gel was 
prepared from 25 ml of a solution containing 6 ml of 29.1% (w/v) 
acrylamide solution, 6 ml of 0.9% (w/v) NJ’-methylencbisacrylamide 
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Fig. 1, Two-dimensional peptide mapping analysis of ‘*P-labeled tryp- 
tic peptides derived from LC phosphorylated by MLCK and PKM. 
Myosin LC phosphorylated by (A) MLCK or (B) PKM in the pres- 
ence of [y-“P]ATP was digested with trypsin and analyzed by electro- 
phoresis on Silica Gel 60 in a buffer containing acetic acid:formic 
acid:H,O (15:8:80, v/v/v) and thin-layer chromatography in n-buta- 
nol:pyridine:acetic acid:H,O (195:150:30:20, v/v/v). The “P-labeled 
peptides were visualized by autoradiography. 
solution, 9 g urea, and 0.5 ml each of Ampholine, pH 2.5-4,3.5-5 and 
5-8. Gel was polymerized by the addition of 10 pl of TEMED and 80 
~1 of 10% ammonium persulfate. ‘2P-labeled peptides were detected by 
autoradiography of the dried gel. Peptide mapping with thin-layer 
silica gel plates was carried out by a previously described method [7]. 
3. RESULTS AND DISCUSSION 
Incubation of the LC with purified MLCK resulted 
in the incorporation of approximately 0.8-1.2 mol 32P/ 
mol of LC with one distinct spot on the peptide map 
(Fig. IA). Phospho-amino acid analysis revealed the 
presence of phosphoserine as a major radioactive con- 
stituent and phosphothreonine as a minor one, both of 
which have previously been identified as Serlg and 
Thr’“, respectively [4,5]. PKC catalyzed the incorpora- 
tion of 1.6-2.3 mol 32P/mol into the LC in a Ca2’/PS- 
dependent fashion. Peptide mapping analysis revealed 
the presence of 2 major tryptic phosphopeptides, in 
which one contains Ser’ or Se? and the other Thrg [7]. 
Phosphorylation of LC by PKM resulted in the incor- 
poration of 2.2-3.1 mol 32P/mol of LC and the reaction 
was not affected by the addition of Ca*‘/PS/DAG or 
Ca2+ and calmodulin. Tryptic peptide mapping analysis 
revealed the presence of several phosphopeptides, 
among them one which comigrated with that phospho- 
rylated by MLCK (Fig. lB, spot 3) and the rest (Fig. 
lB, spots 1, 2 and 4) with those phosphorylated by 
PKC. Correspondence of the various tryptic phospho- 
peptides derived from the PKM-phosphorylated LC to 
those from MLCK- and PKC-phosphorylated ones was 
also confirmed by peptide mapping with isoelectric fo- 
cusing on polyacrylamide gel (Fig. 2). A pI=4.5 tryptic 
32P-labeled peptide, containing predominantly Serlg 
(corresponding to spot 3 in Fig. lB), was detected fol- 
lowing phosphorylation of the LC by MLCK (Fig. 2, 
lane 1). PKC catalyzed the phosphorylation of several 
32P- labeled peptides including pI=7.5, containing Thrg 
(corresponding to spot 1 in Fig. 1 B), and pI=5.0 (corre- 
sponding to spot 2 in Fig. 1B) and 3.6 (corresponding 
to spot 4 in Fig. lB), both of which contained a Ser 
residue. We had tentatively identified these latter two 
“P-labeled peptides based on their predicted pIs as Ac- 
Ser’-Ser2-Lys-Arg and Ac-Ser’-Ser*-Lys, respectively, 
resulting from alternate tryptic cleavage at Arg4 and 
Lys3 (Fig. 2, lane 2). Phosphorylation of LC by PKM 
(Fig. 2, lane 3) resulted in the labeling of all those pep- 
tides from LC phosphorylated by MLCK and PKC as 
well as an unidentified one having pI=3.8 (the band 
above pI=3.6). 
Phosphorylation of the LC by MLCK and PKC 
usually reached a near-maximum level of 1 and 2 mol 
32P/mol, respectively, within 1 h of incubation under the 
assay conditions (Fig. 3). Although the initial rate of 
phosphorylation of the LC by PKC and PKM were 
comparable, the PKM-catalyzed reaction always exhi- 
bited a second phase of slower 32P-incorporation to a 
145 
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Fig. 2. Isoelectric focusing analysis of the ‘2P-labeled tryptic peptides 
derived from LC phosphoryiated by MLCK, PKC and PKM. Tryptic 
phosphopeptides from myosin LC phosphorylated by MLCK (lane I), 
PKC (lane 2), and PKM (lane 3) were separated by isoelectric focusing 
on polyacrylamide gel followed by autoradiography of the dried gel 
as described in section 2. The apparent isoelectric points of the ‘*P- 
labeled peptides were assigned after determination of the pH gradient 
of the gel by a surface electrode. 
stoichiometry of >3 mol 32P/mol (Fig. 3A). Addition of 
MLCK after an initial phosphorylation of the LC with 
PKC resulted in a further 32P-incorporation at a rate 
slower than that by MLCK alone. However, addition 
of MLCK following the phosphorylation of the LC with 
PKM resulted in a relatively low level of increment. The 
final levels of phosphorylation by PKM alone, PKM 
plus MLCK and PKC plus MLCK were nearly identi- 
cal. Phosphorylation of the LC by MLCK and followed 
by the addition of either PKC or PKM resulted in a 
similar extent of enhancement in the “P-incorporation 
(Fig. 3B). The rates of phosphorylation of the LC by 
PKC or PKM under these conditions were slower than 
their respective ones without prior incubation with 
MLCK. These results indicate that phosphorylation of 
LC by PKC or PKM retards the subsequent phospho- 
rylation by MLCK and prior phosphorylation of the 
LC by MLCK retards the phosphorylation by PKC or 
PKM. The tryptic phosphopeptides derived from the 
phosphorylated LC under these various assay condi- 
tions were also analyzed by two-dimensional and isoe- 
lectric focusing peptide mappings and confirmed that 
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Fig. 3. Sequential phosphorylation of myosin LC by the combination 
of PKC, PKM and MLCK. (A) LC was incubated with PKM (A.) ot- 
PKC ((I) under the standard assay conditions. After 60 min of incuba- 
tion an aliquot from each reaction mixture was taken and supplemen- 
ted with MLCK (A,.). (B) LC was initially phosphorylated by MLCK 
(:J) for 60 min and followed by PKC (0) or PKM (A). 
PKM can phosphorylate those sites recognized by PKC 
and MLCK. 
The sites in LC phosphorylated by MLCK are lo- 
cated within the sequence of P’4QRATS”NVFAM24, 
which is also likely to be a substrate of PKC. A synthetic 
peptide, Kl3SNH,, corresponding to the amino acid 
sequence of turkey gizzard myosin LC 1 l-22 (KKRPQ- 
RATSNVF) was tested as a substrate of PKC and 
PKM. PKC phosphorylated the peptide with a y,, = 
17.0 + 0.13 ,uM and V,,, = 2373 * 110 nmol/min/mg 
and PKM with a K,,, = 17.3 t 0.28 ,uM and a V,,, = 
3019 f. 298 nmol/min/mg. The V,,,,, values of this sub- 
strate for PKC and PKM are approximately 50% of 
their respective values with histone 111s. Phospho- 
amino acid analysis revealed that the serine residue was 
phosphorylated by both kinases, indicating that the Ser 
residue in the peptide K 13SNH,, corresponding to the 
Ser’” of the LC was the phosphorylation site. This result 
indicates that Set-” of the LC, which has been identified 
as the phosphorylation site of MLCK, is also a potential 
phosphorylation site of PKC and PKM. The relatively 
low activity of PKC as compared to PKM toward this 
site in the intact LC may be due to steric hindrance 
encountered between PKC and LC. 
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Fig. 4. Effect of M I.-9 on the phosphorylation of the LC by PKC, PKM and MLCK. LC was phosphorylated by (A) PKC, (B) PKM or (C) MLCK 
in the pl-cscncc (0) or absence (, ) of 30 PM of ML-Y. Samples were taken for the analysis of 3’P-incorporation. 
The preparation of PKM used in this study was pre- 
pared from a homogeneous PKC preparation and was 
tested to be free of contaminating MLCK by immuno- 
blot analysis with rabbit anti-smooth muscle MLCK 
antibody. Under our experimental conditions the anti- 
body could readily detect 10 ng of MLCK, however, 
without exhibiting any immunoreactivity toward 3 ,ug 
each of PKC and PKM. Furthermore, addition of cal- 
modulin (0.1 yM) to the PKC or Ca” (0.4 mM) and 
calmodulin (0.1 PM) to the PKM reaction mixture did 
not change their respective phosphorylation sites on 
LC. These results indicated that the contamination of 
the immunorcactive MLCK was almost negligible in the 
preparations of PKC and PKM. Previously, MLCK 
was shown to be activated irreversibly by limited pro- 
teolysis with trypsin. The resulting catalytically active 
fragment of the MLCK is independent of Ca” and 
calmodulin. To exclude the possible contamination of 
the proteolytically-activated MLCK, which may be 
lacking the epitope for the anti-MLCK antibody, we 
tested the effect of ML-9, a selective inhibitor of MLCK 
[16], on LC phosphorylation by PKC, PKM and 
MLCK. Under the assay conditions containing 200 ,uM 
ATP, 30pM ML-9 inhibited the initial rate of LC phos- 
phorylation with PKC and PKM by 14 & 2.2% and 17 
f 2.3%, respectively (Fig. 4A and B). In comparison, 
the MLCK- catalyzed phosphorylation of the LC was 
inhibited by 76 + 2.3% in the presence of the same 
concentration of ML-9 (Fig. 4C). The ML-9-mediated 
inhibition of the PKM-catalyzed phosphorylation of 
Ser” in LC, as analyzed by isoelectric focusing of the 
resulting 32P-labeled tryptic peptides, was also much less 
than that of the MLCK-catalyzed one. The low level of 
inhibition of PKC and PKM by ML-9 is expected be- 
cause this inhibitor is not absolutely specific for MLCK; 
the Ki of ML-9 for PKC and MLCK are 54 and 3.8 ,DM, 
respectively [16]. Thus, it is unlikely that the PKM 
preparations contain protease-activated MLCK. 
The results presented in this report demonstrate that 
PKM can phosphorylate both sets of sites in the turkey 
gizzard LC recognized by PKC and MLCK. This con- 
clusion is based on (i) the peptide mapping analysis of 
the LC phosphorylated by these kinases, (ii) measure- 
ment of the stoichiometries of 32P-incorporation into 
LC catalyzed by these kinases, and (iii) the effects of a 
MLCK inhibitor, ML-9, on these kinase-catalyzed reac- 
tions. The PKM-catalyzed phosphorylation of these 
sites was also observed with LC associated with intact 
turkey gizzard heavy meromyosin, suggesting that 
PKM may phosphorylate LC in vivo. Recently, it has 
been suggested that PKC may share a common site with 
MLCK upon phosphorylation of an embryonic smooth 
muscle LC isoform [17]; however, it is unknown wheth- 
er the low level of phosphorylation of the MLCK site 
by a partially purified PKC preparation results from the 
action of PKM. Previously, it has been demonstrated 
that PKM and PKC have similar relative activities for 
histone Hl and myelin basic protein [18]. In contrast, 
human fibrinogen is a better substrate for PKM than 
PKC [ 181. Thus, smooth muscle myosin LC and human 
fibrinogen are a group of substrates that are preferen- 
tially phosphorylated by PKM as compared to PKC. 
The current study provides the first demonstration that 
PKM can, in fact, phosphorylate a new site in LC in 
addition to those recognized by PKC. 
The isolated LC from smooth muscle has been shown 
to be a substrate for a number of kinases, including 
CAMP-dependent protein kinase [ 191, cGMP-dependent 
kinase [20], phosphorylase kinase [21], casein kinase-1 
[21], casein kinase-2 [21], myosin I heavy chain kinase 
[22], protease-activated protein kinase 1 [23] as well as 
PKC and MLCK. Although isolated LC can be phos- 
phoryIated by these kinases in vitro, only MLCK and 
PKC are thought to play major roles in the regulation 
of the actin-activated Mg”-ATPase activity in vivo [2]. 
In human platelets [8] and neutrophiles [24] stimulation 
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of PKC by phorbol ester results in the generation of 
PKM, which could participate in the phosphorylation 
of cellular proteins including the LC. The actions of 
PKM inside the cells have also been demonstrated by 
microinjection of PKM into NIH3T3 cells that resulted 
in morphological changes of these cells comparabIe to 
those induced by PMA [25]. It seems likely that the 
PMA-induced generation of PKM could bring about a 
broader cellular responses, due to an enhanced kinase 
activity, than the activation of PKC induced by a ligand 
without causing its degradation. 
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